Print this page
Friday, 15 January 2016 00:00

Hepatitis C Treatments Viekira Pak And Technivie: Risk Of Serious Liver Injury

Rate this item
(0 votes)

The National Agency for Food and Drug Administration and Control (NAFDAC) has been notified by the U.S Food and Drug Administration (FDA) of the safety concerns on hepatitis C treatments Viekira Pak and Technivie. Viekira Pak and Technivie, are oral antiviral agents used in the treatment of chronic hepatitis C, a viral infection that can last a lifetime and lead to serious liver and other health problems, including cirrhosis, liver cancer, and death. These medicines reduce the amount of hepatitis C virus in the body by preventing it from multiplying and may slow down the disease.

It is warned by the FDA that hepatitis C treatments Viekira Pak and Technivie can cause serious liver injury mostly in patients with underlying advanced liver disease. According to FDA, several cases of liver injury in patients using either drug have been reported within 1 to 4 weeks of starting treatment.

 As a result, FDA is requiring the manufacturer AbbVie Inc. to add new information about this safety risk to the drug labels.

Possible associated Risks

  • Hepatic decompensation and liver failure could result from such an exposure to these drugs especially in patients with underlying liver cirrhosis.
  • Liver injury could require liver transplant for patient to stand a chance of survival.
  • Death results when prompt accurate medical intervention has not been made.

Action required from Prescriber/Patients

NAFDAC….Safeguarding the health of the Nation

Read 7497 times Last modified on Wednesday, 18 May 2016 14:24